Guidance for Teva Pharmaceutical Industries Limited (TEVA)
Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
---|---|---|---|---|---|---|
2023 | $2.25 – $2.55 | $2.28 | $15.10B – 15.50B | $15.14B | = Maintained | Details |
2023 | $2.25 – $2.55 | $2.39 | $14.80B – 15.40B | $15.04B | = Maintained | Details |
2023 | $2.25 – $2.55 | $2.51 | $14.80B – 15.40B | $15.20B | = Maintained | Details |
2023 | $2.25 – $2.55 | $2.27 | $15.00B – 15.40B | $15.02B | = Maintained | Details |
2022 | $2.40 – $2.60 | $2.51 | $15.40B – 16.00B | $15.97B | Lowered | Details |
2022 | $2.40 – $2.60 | $2.50 | $14.80B – 15.40B | $15.46B | Lowered | Details |
2022 | $2.40 – $2.60 | N/A | $15.00B – 15.60B | N/A | = Maintained | Details |
Q1 2022 | $2.40 – $2.60 | $2.64 | $15.60B – 16.20B | $16.32B | = Maintained | Details |
2021 | $2.50 – $2.70 | N/A | $16.00B – 16.40B | N/A | = Maintained | Details |
2021 | $2.50 – $2.70 | $2.61 | $16.40B – 16.80B | $16.68B | = Maintained | Details |
2021 | $2.50 – $2.70 | $2.63 | $16.40B – 16.80B | $16.76B | = Maintained | Details |
2021 | $2.50 – $2.70 | $2.45 | $16.00B – 16.40B | $16.55B | Lowered | Details |
2020 | $2.30 – $2.55 | $2.44 | $16.60B – 17.00B | $16.70B | = Maintained | Details |
2020 | $2.40 – $2.55 | $2.51 | $16.50B – 16.80B | $16.70B | = Maintained | Details |
2020 | $2.30 – $2.55 | $2.50 | $16.60B – 17.00B | $16.80B | = Maintained | Details |
2019 | $2.20 – $2.50 | $2.81 | $17.00B – 17.40B | $17.93B | Lowered | Details |
2019 | $2.30 – $2.50 | $2.38 | $17.20B – 17.40B | $17.18B | = Maintained | Details |
2018 | $2.25 – $2.50 | $2.94 | $18.30B – 18.80B | $19.26B | = Maintained | Details |
2018 | $2.40 – $2.65 | $2.48 | $18.50B – 19.00B | $18.70B | = Maintained | Details |
2018 | $2.80 – $2.95 | $2.78 | N/A | N/A | Raised | Details |
2018 | $2.55 – $2.80 | $2.69 | N/A | N/A | Raised | Details |
Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q3 2017 | $4.30 – $4.50 | $4.74 | N/A | N/A | = Maintained | Details |
Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
2016 | $5.10 – $5.20 | $5.16 | $21.60B – 21.90B | $22.10B | = Maintained | Details |
2016 | $5.20 – $5.40 | $5.30 | $22.00B – 22.50B | $22.30B | = Maintained | Details |
Q4 2016 | $1.34 – $1.44 | $1.42 | $6.20B – 6.50B | $6.48B | = Maintained | Details |
Q1 2016 | $1.32 – $1.36 | $1.21 | $4.70B – 4.90B | $4.92B | = Maintained | Details |
2015 | $5.15 – $5.40 | $5.26 | N/A | N/A | Raised | Details |
2015 | $5.40 – $5.45 | $5.32 | N/A | N/A | Raised | Details |
2014 | $4.90 – $5.10 | $4.82 | N/A | N/A | Raised | Details |
2013 | $4.95 – $5.05 | $5.00 | $19.70B – 20.30B | $20.06B | = Maintained | Details |
2012 | $5.32 – $5.38 | $5.36 | $20.10B – 20.70B | $20.47B | = Maintained | Details |